The Patent Finder
DM

Disc Medicine, Inc.

First filing 2021
OverviewNotableFeesChangesFamiliesPatent listSources & methods

Three patents currently held, every record listed here

5 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in Jan 2041. from the record

Of the 5 now held by other companies, 5 name AbbVie Deutschland GmbH and Co. KG as their current owner. Each row says so.

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Jan 2041
Next term end
2
Patent families

When these terms end

Each bar runs from grant to computed term end. 2023 to 2043.
US 12,715,916 Anti-Hemojuvelin (HJV) Antibodies for Treating Myelofibrosis May 13, 2040
US 12,715,917 Methods of Using Anti-Hemojuvelin (HJV) Antibodies for Treating Myelofibrosis no later than May 13, 2040
US 12,721,847 Methods of Treating Erythropoietic Protoporphyria, X-Linked Protoporphyria, or Congenital Erythropoietic Porphyria with Glycine Transport Inhibitors Jan 8, 2041
US 12,365,729 Anti-Hemojuvelin (HJV) Antibodies for Treating Myelofibrosis May 13, 2041
US 12,497,452 Anti-Hemojuvelin (HJV) Antibodies for Treating Myelofibrosis May 13, 2041
US 11,813,257 Methods of Treating Erythropoietic Protoporphyria, X-Linked Protoporphyria, or Congenital Erythropoietic Porphyria with Glycine Transport Inhibitors Jan 8, 2042
US 12,428,415 Matriptase 2 Inhibitors and Uses Thereof May 31, 2042
US 12,655,210 Anti-Hemojuvelin (HJV) Antibodies for Treating Anemia of Chronic Disease Mar 5, 2043
20272031203520392043
A dotted end marks a recorded terminal disclaimer this site has not resolved: the term can only be shorter than the bar, never longer.
19 pending applications: term is not computable until grant.Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Only 2 of the currently held patents qualify as notable.

Formerly held, still cited

Notable
A family of 7 related applications built on the 2026 grant. Too new for citation comparison; protection runs to 2040. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
Ends no later than May 2040 · Medium confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due May 14, 2027
    The maintenance fee for Methods of Treating Erythropoietic Protoporphyria, X-Linked Protoporphyria, or Congenital Erythropoietic Porphyria with Glycine Transport Inhibitors (US 11,813,257) comes due May 14, 2027. Unpaid by Nov 15, 2027, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 3 of the patents on this record were granted since Aug 20, 2026

What they patent

Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.

Patents held now

Soonest term end first.

Showing 1 to 3 of 3

PatentTitleStatusExpiresConfidence
US 12,721,847Methods of Treating Erythropoietic Protoporphyria, X-Linked Protoporphyria, or Congenital Erythropoietic Porphyria with Glycine Transport Inhibitors
In force
 · High confidence
In forceHigh confidence
US 11,813,257Methods of Treating Erythropoietic Protoporphyria, X-Linked Protoporphyria, or Congenital Erythropoietic Porphyria with Glycine Transport Inhibitors
In force
 · High confidence
In forceHigh confidence
US 12,428,415Matriptase 2 Inhibitors and Uses Thereof
In force
 · High confidence
In forceHigh confidence
Also on record, not counted in the 3: 5 patents in force now held by others · 19 applications pending · 6 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
1 terminal disclaimer is on file with no resolved reference. No cap is applied and none is guessed
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited